首页|期刊导航|中成药|基于Hippo/YAP通路探讨补肾强督治偻汤对强直性脊柱炎异位骨化的改善作用

基于Hippo/YAP通路探讨补肾强督治偻汤对强直性脊柱炎异位骨化的改善作用OA

Improvement effect of Bushen Qiangdu Zhilou Decoction on heterotopic ossification in ankylosing spondylitis based on the Hippo/YAP pathway

中文摘要英文摘要

目的 探究补肾强督治偻汤对强直性脊柱炎(AS)异位骨化的影响.方法 体内实验:将BALB/c小鼠随机分为空白组、模型组、塞来昔布组(70mg/kg)及补肾强督治偻汤低、中、高剂量组(18.5、37、74 g/kg),采用胶原抗体诱导法构建AS异位骨化小鼠模型,造模第10天灌胃给药至第42天.记录小鼠一般情况及足踝关节肿胀情况,micro-CT、HE染色、番红固绿染色评估关节异位骨化情况,转录组测序筛选核心信号通路.体外实验:以髋关节韧带成纤维细胞为研究对象构建韧带成纤维细胞成骨分化模型,分别给予低、中、高剂量补肾强督治偻汤(0.25、0.5、1 mg/mL),CCK-8法检测细胞活性,ALP染色和茜素红染色评估成骨分化水平,Western blot法检测成骨标志物RUNX2、Col1a1、OPN蛋白表达及Hippo/YAP通路相关蛋白LATS、YAP表达及磷酸化水平,免疫荧光法检测Hippo/YAP蛋白核定位情况与表达.结果 体内实验:与模型组比较,补肾强督治偻汤各剂量组及塞来昔布组未产生体质量及肝脏、脾脏、肾脏脏器指数变化(P>0.05),补肾强督治偻汤中剂量组小鼠关节肿胀度降低(P<0.05),各剂量组异位骨化程度减轻,新骨组织体积减少(P<0.01).转录组学分析提示Hippo/YAP通路是补肾强督治偻汤发挥作用的核心通路之一.体外实验:与模型组比较,补肾强督治偻汤各剂量组ALP染色阳染面积减少(P<0.01),茜素红染色阳染面积减少(P<0.05,P<0.01),成骨相关标志物蛋白Col1a1、SOX9、RUNX2、OPN表达降低(P<0.05,P<0.01),成骨相关标志物ALP、Col1a1、RUNX2 mRNA表达降低(P<0.05),Hippo/YAP通路相关蛋白磷酸化水平(p-LATS/LATS、p-YAP/YAP)升高(P<0.05),YAP 总蛋白表达及核内荧光强度降低(P<0.05,P<0.01).结论 补肾强督治偻汤可能通过激活Hippo/YAP通路,抑制韧带成纤维细胞YAP核转位及下游成骨基因转录,从而减轻AS异位骨化.

AIM To investigate the effect of Bushen Qiangdu Zhilou Decoction on heterotopic ossification in ankylosing spondylitis(AS).METHODS In vivo experiment:BALB/c mice were randomly divided into a blank group,a model group,a celecoxib group(70 mg/kg),and low-,medium-,and high-dose Bushen Qiangdu Zhilou Decoction groups(18.5,37 and 74 g/kg).The AS heterotopic ossification mouse model was established using the collagen antibody-induced method.From day 10 to day 42 after modeling,the mice were administered by gavage.The general condition and ankle joint swelling of the mice were recorded.Micro-CT,HE staining,and safranin O-fast green staining were used to evaluate joint heterotopic ossification.Transcriptome sequencing was performed to screen for core signaling pathways.In vitro experiment:Hip joint ligament fibroblasts were used to construct an osteogenic differentiation model of ligament fibroblasts.Low-,medium-,and high-dose Bushen Qiangdu Zhilou Decoction(0.25,0.5 and 1 mg/mL)were administered,respectively.Cell viability was detected by CCK-8 assay.ALP staining and alizarin red staining were used to evaluate the level of osteogenic differentiation.Western blot was used to detect the protein expressions of osteogenic markers RUNX2,Col1a1,and OPN,as well as the expressions and phosphorylation levels of Hippo/YAP pathway-related proteins LATS and YAP.Immunofluorescence was used to detect the nuclear localization and expressions of Hippo/YAP proteins.RESULTS In vivo experiment:Compared with the model group,there were no significant changes in body weight and organ indices of the liver,spleen,and kidney in the Bushen Qiangdu Zhilou Decoction groups of various doses and the celecoxib group(P>0.05).The joint swelling degree was reduced in the medium-dose Bushen Qiangdu Zhilou Decoction group(P<0.05).The degree of heterotopic ossification was alleviated,and the volume of new bone tissue was decreased in all dose groups(P<0.01).Transcriptomic analysis indicated that the Hippo/YAP pathway was one of the core pathways through which Bushen Qiangdu Zhilou Decoction exerts its effects.In vitro experiment:Compared with the model group,the positive staining areas of ALP were significantly reduced in all dose groups of Bushen Qiangdu Zhilou Decoction(P<0.01).The positive staining areas of alizarin red were decreased(P<0.05,P<0.01).The protein expressions of osteogenesis-related markers Col1a1,SOX9,RUNX2,and OPN were down-regulated(P<0.05,P<0.01),and the mRNA expressions of ALP,Col1a1,and RUNX2 were decreased(P<0.05).The phosphorylation levels of Hippo/YAP pathway-related proteins(p-LATS/LATS,p-YAP/YAP)were increased(P<0.05).The total protein expression and nuclear fluorescence intensity of YAP were decreased(P<0.05,P<0.01).CONCLUSION Bushen Qiangdu Zhilou Decoction may alleviate AS heterotopic ossification by activating the Hippo/YAP pathway,inhibiting the nuclear translocation of YAP in ligament fibroblasts,and suppressing the transcription of downstream osteogenic genes.

陈柏臻;曾睿;周海燕;杨璐;陈美琪;周颖燕;马梦洋;何羿婷;何晓红

广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000||广东省中医证候临床研究重点实验室,广东 广州 510000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000河南省洛阳正骨医院(河南省骨科医院),河南郑州 450000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000||广东省中医证候临床研究重点实验室,广东 广州 510000广州中医药大学第二临床医学院,广东 广州 510000||广州中医药大学第二附属医院(广东省中医院),广东 广州 510000

医药卫生

补肾强督治偻汤强直性脊柱炎病理性新骨形成转录组学Hippo/YAP通路

Bushen Qiangdu Zhilou Decoctionankylosing spondylitispathological new bone formationtranscriptomicsHippo/YAP pathway

《中成药》 2026 (8)

2587-2599,13

国家自然科学基金(82174285)广东省名中医传承工作室建设项目(0102018004)广州市科技局市院联合资助项目(2024A03J0718)广东省中医院院内专项(YN2024GZRPY086)广东省中医院临床研究专项(YN10101905)

10.3969/j.issn.1001-1528.2026.08.012

评论